Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, […]
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the […]
FAP session at Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting attracts packed audience
SOFIE hosted a FAP session, together with Clovis […]
SOFIE FAPI Clinical Development Update
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
2022 Annual SNMMI Meeting – Vancouver, Canada
June […]
FAP-Ligand PET Update ≠ Cancer
Presented by: Professor Jeremie Calais, MD, MSc, Professor, University of California, Los Angeles
2022 Annual SNMMI […]
Fibroblast Activation Protein (FAP) – A promising target for radiopharmaceuticals
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
June 8, 2022 Download the Presentation […]
Pitfalls and Common Findings in 68 Ga-FAPI PET: A Pictorial Analysis
Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Fadi Zarrad, Michael Nader, David Kersting, […]
SOFIE Opens 20,000 sq ft Theranostics Center of Excellence
Dulles, VA, April 27, 2022– SOFIE Co. (SOFIE), a Theranostics company, commissions its new […]
Comparison of 68 Ga-FAPI PET/CT and 18 FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement
Umut Elboga, Ertan Sahin, Tulay Kus, Yusuf Burak Cayirli, Gokmen Aktas, Merve […]